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Orthopedic implants have revolutionized treatment of bone fractures and noninfectious joint arthritis. Today,
the risk for orthopedic device–related infection (ODRI) is !1%–2%. However, the absolute number of patients
with infection continuously increases as the number of patients requiring such implants grows. Treatment of
ODRIs most frequently includes long-term antimicrobial treatment and removal of the implant. Recent evi-
dence from observational trials and 1 randomized clinical trial indicate that a subset of patients can be
successfully treated with retention of the implant. Patients eligible for such a treatment must meet the following
criteria: acute infection defined as signs and symptoms lasting !14–28 days, an unambiguous diagnosis based
on histopathology and microbiology, a stable implant, and susceptibility of the microorganism to an effective
orally available antimicrobial agent.
Orthopedic implants have become an essential com-
ponent of modern medicine. More than 200,000 total
hip replacements are performed annually in the United
States and 150,000 in the United Kingdom [1]. The
safety and biocompatibility of these devices are excel-
lent, and !10% of the patients at risk experience com-
plications during their lifetime [2]. Arthroplasty has
become the treatment of choice for patients aged 55
years with severe pain and disability from knee arthritis
[3]. Because the percentage of patients aged 165 years
is on the rise in industrialized countries, the number
of patients requiring implants will continue to grow, as
will the risk for orthopedic device–related infections
(ODRIs). In the United States, 14.4 million people have
at least 1 internal fixation device and 11.3 million have
an artificial joint [4].
Sophisticated prevention strategies have been devel-
oped during the past 2 decades to lower the risk of
infectious complications in implant surgery. Examples
include laminar airflow with ultraclean air [5], routine
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antimicrobial prophylaxis [6], short operating time, use
of antibiotic-bonded cement [7], and antimicrobial
coating [8, 9]. Although incidence of ODRIs is now
low—internationally !1%–2% in institutions with high-
ly trained surgeons [10]—even a very low risk of in-
fection can result in a number of patients with ODRIs.
Such patients are mainly treated at the institution where
the prosthesis had been implanted. The scarcity of in-
fections per institution may explain why treatment of
such an infection is poorly standardized. Randomized
controlled clinical trials are hampered by the fact that
only large institutions have sufficient numbers of pa-
tients to enroll and that successful treatment requires
a follow-up of 12 years. Therefore, such studies fre-
quently lack appropriate statistical power because of pa-
tients being lost to follow-up, changing residence, or
dying of underlying diseases. The publication of such a
study took 6 years from design until results from the 2-
year follow-up were available [11]. Moreover, diagnosis
and management require close collaboration between
surgeons, infectious disease specialists, microbiologists,
and pathologists, and internationally accepted criteria for
diagnosis and consecutive treatment of ODRIs have not
been developed. Therefore, the diagnosis refers more to
surgical criteria in studies conducted by surgeons and
relies predominantly on microbiological data in studies
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guided by microbiologists. Not surprisingly, the various criteria
for diagnosis and multifaceted approaches for treatment have led
to diverse conclusions and recommendations.
Simple surgical drainage with retention of the prosthesis in
situ and treatment with antimicrobial agents have been asso-
ciated with failure rates of 60%–80% [12, 13]. However, more
recent studies have cited failure rates of !20% when a stan-
dardized protocol for salvage treatment was used [11, 14, 15].
A nonoperative or minimally invasive surgical approach is at-
tractive for both patient and clinician, especially because most
patients with prosthetic joints are elderly and have significant
comorbidities. Proper selection of patients allows successful
treatment of infection, with salvage of the implant. However,
careful evaluation of the patients, their underlying diseases, the
type of implant, the quality of the bone stock, and an unam-
biguous diagnosis of infection are prerequisites for successful
management of such infections. Appropriate treatment achieves
cure rates of 180% with retention of the device, reducing mor-
bidity, mortality, and cost of treatment of ODRIs. Nevertheless,
only a subset of patients qualifies. In general, infections asso-
ciated with internal fixation devices rather than joint prostheses
respond better to salvage. Infections associated with total knee
prostheses are more difficult to manage than are those asso-
ciated with total hip prostheses. This review focuses on new
developments in diagnosis and treatment of ODRIs, with em-
phasis on strategies of retaining the device.
PATHOGENESIS OF ODRIS
Biofilm formation. The pathogenesis of ODRIs has been
reviewed elsewhere and is beyond the scope of this review [16].
However, an understanding of the pathogenesis of biofilm for-
mation facilitates optimal diagnosis and treatment. In addition,
it explains why signs and symptoms are relieved by short-term
treatment with antimicrobial agents but reoccur immediately
after withdrawal of treatment [17]. All implants undergo phys-
iological changes after implantation. The earliest and probably
clinically the most important step is the “race for the surface,”
a contest between tissue cell integration and bacterial adhesion
to that same surface [18]. On contact, body fluids immediately
coat all surfaces with a layer of host material, primarily serum
proteins and platelets. Albumin, as the major serum compo-
nent, is rapidly deposited on foreign material and prevents
nonspecific neutrophil activation and deposition of matrix pro-
teins on the surfaces [19]. Adherence of Staphylococcus aureus
to bioprosthetic materials is mediated by adhesins, such as
fibronectin, fibrinogen, fibrin, collagen, laminin, vitronectin,
thrombospondin, bone sialoprotein, elastin, and the matrix-
binding protein. These host proteins promote attachment of S.
aureus onto polymeric or metallic surfaces by specific receptors.
Such mechanisms are ill-defined for coagulase-negative staph-
ylococci (CNS), because most studies are done in the absence
of proteins [20]. Adherence progresses to aggregation of mi-
croorganisms on the surface of the foreign body, forming a
biofilm. As the colonies mature, sessile bacteria on the periph-
ery detach and disperse as planktonic bacteria. This process
can lead to clinically overt infection but rarely to bacteremia.
Costerton et al. [21] defined bacterial biofilms as “structured
communities of bacterial cells enclosed in a self-produced poly-
meric matrix and adherent to an inert or living surface.” Both
types of surfaces are frequently present in ODRIs: the medical
device and sequestra of dead bone. Biofilms grow slowly and
can resist cellular and humoral immune responses [22]. More-
over, several mechanisms render biofilm bacteria less suscep-
tible to antimicrobial agents than their planktonic counterparts.
Cell-to-cell signals, involved in the development of the bacterial
biofilm in Pseudomonas aeruginosa, may provide a new target
to control biofilm formation, but they have not yet been doc-
umented for other bacteria [23]. Clinically established mech-
anisms include adherence of bacteria, slime production, and
slow rate of bacterial growth. Bacteria become sessile in the
biofilm, and their phenotypic features change considerably.
They become resistant through several mechanisms that are
still a major topic of research. The 2 clinically important mech-
anisms are failure of antimicrobial agents to penetrate the bio-
film and the stationary phase of growth. In addition, some
bacteria, such as S. aureus, form small-colony variants, char-
acterized by reduced growth rate, diminished exoprotein pro-
duction, decreased susceptibility to aminoglycosides, and pos-
sible intracellular persistence [24]. Standard antibiotic therapy
typically reverses signs and symptoms caused by planktonic
bacteria released from the biofilm but fails to kill bacteria in
the biofilm [21]. Therefore, successful treatment of ODRIs with
retention of the implant incorporates treatment against both
planktonic and sessile bacteria. Another option is to kill plank-
tonic bacteria by antimicrobial agents and to get rid of sessile
bacteria by removing the implant [21].
Slime production. A variety of microorganisms, particu-
larly CNS but also P. aeruginosa and Streptococcus mutans, de-
velop slime, an amorphous extracellular glycocaliceal substance
based on polysaccharide. Electron microscopy clearly shows
implants quickly covered by several layers of slime. Slime pro-
duction is usually triggered by adherence to surfaces but is also
a property of a particular strain. Many strains of CNS isolated
from clinically significant infections exude slime. Slime ex-
tracted from CNS grown on chemically defined medium con-
sists of 80% teichoic acid and 20% protein [25]. Glycocalix
promotes intercellular adhesion, captures nutrients, and pro-
tects microorganisms from the deleterious effects of anti-
microbial agents. Many investigators consider slime a virulence
factor, because strains of CNS from prosthetic valve endocar-
ditis are more likely to produce it than are those not cultured
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from such infections [26]. Christensen et al. [27] clearly showed
that slime-producing CNS are more likely to be isolated from
a device than from random blood cultures. However, its pro-
duction appears as a heterogeneous phenomenon in which
there is unequal expression of slime by individual daughter
cells from the same strain. Slime has potent immunomodu-
latory properties and alters the susceptibility of the microor-
ganisms to antimicrobial agents. Slime can decrease chemotaxis
and opsonization of neutrophil granulocytes, increase degran-
ulation, and block penetration of antibiotics into the bacterial
cell [28].
Mode of growth. Bacteria in a biofilm do not grow ex-
ponentially. They exist in a slow-growing or starved state (i.e.,
stationary phase) [21]. Studies of ODRIs in an animal model
confirmed the slow-growing or starved state of bacterial growth
for S. aureus and Escherichia coli. The MICs determined ac-
cording to recommendations by the National Committee for
Clinical Laboratory Standards do not accurately reflect con-
ditions observed in ODRIs [29]. In addition, standard suscep-
tibility testing measures the inhibitory activity of an antimicrobial
agent, but bactericidal activity appears to be fundamental for
successful treatment of ODRIs. Attempts have been made to
improve routine susceptibility testing by measuring MBCs, kill
curves, and serum bactericidal titers. These methods test plank-
tonic bacteria in logarithmic phase of growth but are difficult to
interpret. MBCs are defined as 99.9% killing. A very few or-
ganisms (usually !0.1% of the final inoculum) survive the lethal
effect of an antibiotic, even if they turn out to be highly re-
sponsive to standard susceptibility testing. This phenomenon
is thought to result from the fact that some cells are dormant
or replicating slowly and, consequently, are not killed by the
antibiotic, a situation quite similar to the conditions observed
in ODRIs.
Therefore, we performed susceptibility testing in parallel with
exponentially growing bacteria and bacteria in a slow-growing
state to better simulate conditions observed in ODRIs. Much
higher concentrations were needed to kill stationary-phase bac-
teria than logarithmically growing bacteria [30, 31], and several
investigators confirmed these findings [21, 32, 33]. Costerton
et al. [34] and the National Committee for Clinical Laboratory
Standards proposed guidelines in the early 1990s to test anti-
microbial efficacy against stationary-phase bacteria. They called
it “biofilm-eliminating concentration,” or BEC. In our model
[30, 31], killing depended not only on the antimicrobial agent
but also on the microorganism. Rifampin alone was highly
effective against stationary-phase gram-positive cocci such as
Staphylococcus epidermidis and S. aureus. Moreover, the MBC
of rifampin determined for stationary-phase bacteria remained
in a range achievable in serum and tissue with a standard dosage
of rifampin in humans. The MBCs of ciprofloxacin increased
200 times when tested with stationary-phase S. epidermidis. In
contrast, ciprofloxacin was highly efficacious against stationary-
phase Salmonella dublin and E. coli ATCC 25922. These ob-
servations are supported by experiments by Zeiler and col-
leagues [33, 35] and other investigators [30, 31]. They also
showed good activity of ciprofloxacin against stationary-phase
bacilli such as E. coli. The mode of action remains unclear, but
these tests correlated much better with the results of the guinea
pig model and human studies than did routine susceptibility
testing and regular MBCs [30, 31].
Why some antimicrobial agents perform better than others
against stationary-phase bacteria is poorly understood. The re-
duced efficacy of b-lactam antibiotics may be explained in part
by their primary mode of action. Their killing is growth-de-
pendent, and, hence, slow-growing bacteria in device-related
infections are not as affected as those growing logarithmically
in the laboratory. However, other complex interactions, in-
cluding slime production, can inhibit antimicrobial activity of,
for example, glycopeptides [36]. More research is needed to
clarify the role of slime in the pathogenesis of device-related
infections. Results of several authors indicate that an antimi-
crobial agent should be bactericidal against slow-growing bac-
teria for optimal effectiveness [11, 30, 33]. In general, a 10–100-
times higher concentration than the MIC is required to achieve
this desired activity, but success also depends on species, strain,
and antimicrobial agent.
NOMENCLATURE OF ODRIS
As mentioned above, an internationally accepted classification
for ODRIs has not yet been established. Such a classification
could guide the management of these infections and facilitate
the comparison of approaches from different institutions. Con-
ventry [37] proposed a frequently used classification (table 1),
which has been adapted by reducing the time frame for early
infection from 3 months to 1 month [38]. Current clinical
evidence indicates that with immediate treatment of acute in-
fection (!2 weeks after onset of signs or symptoms), the implant
can be salvaged [11, 12, 39]; therefore, the current classification
should probably be adapted to define early postoperative in-
fections as occurrence of signs or symptoms from !14 days to
a maximum of 28 days after surgery (table 1). The best evidence
is based on a randomized clinical trial: All patients who were
able to complete the treatment plan and began treatment within
!1 week of clinical onset were cured [11]. Other groups sup-
ported these data with retrospective studies [2, 12, 13, 40].
Tsukayama et al. [40] included a group of patients with “in-
traoperative positive cultures,” who were operated on with the
presumptive diagnosis of aseptic loosening of the device with-
out signs or symptoms of infection. Routine cultures unex-
pectedly revealed at least 2 positive specimens with the same
microorganism. Because CNS were isolated in 71% of these
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Table 1. Nomenclature of orthopedic device–related infections.
Infection category
Typical onset
after surgery Type Signs and symptoms Representative microorganism
Early postoperative 2–4 weeks Acute (type I) Persistent pain after surgery, fever,
redness, swelling after surgery
Staphylococcus aureus, coagulase-
negative staphylococci
Late chronic 1 month Chronic (type II) Insidious onset, persisting pain after
surgery
Coagulase-negative staphylococci,
Propionibacterium species,
anaerobes, S. aureus
Hematogenous 12 years Acute (type III) Fever, pain, redness, swelling after
a long period of wellness
Streptococci, S. aureus, gram-
negative bacilli
Table 2. Criteria for patients to be considered for treatment of
orthopedic device–related infections with salvage of implant.
Criterion
Acute infection with signs and symptoms of 14–28 days
Stable implant with no signs or symptoms of loosening
Clearly established diagnosis by isolating single microorganism
from multiple specimens by aspiration or preferably intraopera-
tive culture during debridement
Positive histopathologic results, preferably by frozen section
Pathogen susceptible to oral, preferably bactericidal, antimicrobial
agent
Antimicrobial agent with proven effectiveness in preferably human
(see table 5) or animal studies
Patient able and willing to undergo long-term antimicrobial therapy
cases, indicating low-grade chronic infection, these patients
should be included in the group of chronic infection with low-
virulence pathogens.
Early postoperative infections. These occur in the im-
mediate postoperative period, representing a classic surgical site
infection [41] as defined by the Centers for Disease Control
and Prevention. The patient usually presents with fever, chills,
and sweating. Pain persists in the early postoperative period
and does not decline as in noninfected patients. The wound
may be erythematous, swollen, fluctuant, and tender. A diag-
nostic challenge is the distinction between a superficial infection
and the contiguous infection deep to the fascia and around the
implant [2]. Empirical treatment with antimicrobial agents may
mitigate signs or symptoms of infection but will ultimately
result in chronic infection and is not recommended. Therefore,
such patients require a rapid workup for suspected early in-
fection and qualify for implant salvage given the circumstances
listed in table 2.
Late chronic infection. Chronic infections likely originate
at the time of surgery. A very low inoculum or a low-virulence
pathogen such as CNS delays the onset of clinically apparent
infection and does not trigger symptoms of acute infection.
The typical onset of this type of infection is between 16 months
and 2 years [10]. The hallmark is gradual deterioration in func-
tion and concurrent intensifying pain. Early loosening of the
implant may be the only symptom of chronic infection in pa-
tients with a joint prosthesis. The distinction between aseptic
loosening of a prosthesis and low-grade chronic infection re-
mains a challenge despite advances in diagnostic tools. Such
an infection responds poorly to treatment with antimicrobial
agents with retention of the device, even after extensive de-
bridement.
Hematogenous infection. The hallmark of this type of
infection is a sudden, rapid deterioration in the function of an
implant that was functioning well for a long period after surgery
[10]. It occurs almost exclusively in joint prostheses. Most in-
fections are observed 12 years after surgery, presenting with
signs and symptoms similar to early postoperative infection.
Hematogenous seeding may be triggered by dental manipula-
tion, catheter-associated urinary tract infection and urosepsis,
and remote infection. Not surprisingly, streptococci are more
frequently isolated in this type of infection than in others.
Patients at risk for hematogenous seeding are those under im-
munosuppression for inflammatory arthropathy or transplant
patients. Immediate workup of patients with these signs or
symptoms is crucial. Such an infection may also qualify for
salvage treatment.
MICROORGANISMS IN ODRIS
Staphylococci are the most frequently encountered micro-
organisms isolated from patients with ODRIs (table 3), account-
ing for ∼50% of the cases [44]. Others are anaerobes, gram-
negative bacilli such as Pseudomonas species or E. coli, and,
especially in hematogenous infections, streptococci [2, 13]. Tun-
ney et al. [45] isolated Propionibacterium species in 60% of ODRIs
by using strict anaerobic bacteriologic practices during the pro-
cessing of samples considered associated with ODRIs. Propion-
ibacterium species are the second most frequent contaminant
observed in joint aspiration [46]. Multiple organisms are fre-
quently isolated from such samples, which may indicate polymi-
crobial infection but raises the possibility that one microorganism
may be responsible for infection and the other may be a con-
taminant. Molecular diagnostic tools will likely render the in-
terpretation of microbiological results even more difficult. How-
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Table 3. Microorganisms isolated from
orthopedic device–related infections.
Microorganism %
Coagulase-negative staphylococci 20–25
Staphylococcus aureus 20–25
Polymicrobial 14–19
Gram-negative bacilli 8–11
Streptococci 8–10
Anaerobesa 6–10
Enterococci 3
Other 10
a Positive anaerobic culture depends on transport
media used in operating room and microbiological
technique.
ever, multiple specimens for culture should be taken from any
suspected infection site, and the clinician should put samples in
transport media for anaerobic microorganisms. Results of mul-
tiple specimens will facilitate interpretation of the culture results.
A single positive result for a particular microorganism from cul-
ture of 3 specimens of skin usually signifies contamination,
whereas presence of an organism in all 3 specimens, even Pro-
pionibacterium species, indicates infection. Additional informa-
tion from the microbiology laboratory may help to suggest true
infection, such as short time to positivity, massive growth in
cultures, and the resistance pattern of the pathogen. For example,
isolation of a penicillin-susceptible CNS endorses a diagnosis of
contamination, because most CNS are penicillin-resistant. How-
ever, some cases remain unclear even after reviewing all clinical,
microbiological, and histological data available. The high likeli-
hood of contamination precludes the routine use of microbio-
logical culture for ODRIs without clinical signs or symptoms of
infection, unless multiple specimens are taken for microbiology
and histopathology. Nevertheless, some patients scheduled for
routine replacement do not present with overt signs or symptoms
of infection, and diagnosis of ODRI is made exclusively by in-
traoperative culture and histopathology. This applies specifically
to patients with suspected diagnosis of aseptic loosening of the
implant, who require a very careful workup.
DIAGNOSTIC WORKUP
No preoperative tests are consistently sensitive and specific for
infection in patients who need a revision arthroplasty. Inter-
pretation of the investigative tests are easier for internal fixation
devices than for joint prostheses. Definitive diagnosis based
solely on history and physical findings may prove inaccurate.
However, a careful history of the patient and risk assessment
is mandatory for all patients with evidence of ODRI. A recent
case-control study clearly established several risk factors for the
development of ODRI in patients with prosthetic joints. The
most important was a postoperative surgical site infection (OR,
35.9) [41], followed by a high NNIS (National Nosocomial
Infections Surveillance) system score (OR, 3.9), systemic ma-
lignancy (OR, 3.1), and prior joint arthroplasty (OR, 2.0) [42].
Knee arthroplasties are associated with a higher risk of infection
(2%) than hip are arthroplasties (1.3%) [47], as are, in general,
revision procedures [47]. Although these data are epidemiol-
ogically important, they are of little help in evaluating the in-
dividual patient with an implant. The only consistent clinical
finding in ODRIs is pain at the site of the implant. Hematologic
testing results, erythrocyte sedimentation rates (ESR), C-reac-
tive protein (CRP) levels, and x-rays and bone scan results are
highly variable. In addition, the sensitivity of standard micro-
biological cultures does not exceed 70% [48]. Only the sum of
clinical signs and symptoms, blood tests, radiography, bone
scans, and a microbiological workup can provide an accurate
diagnosis. However, a score to ultimately establish the diagnosis
has not been widely used. Therefore, one should know about
the impact of a positive test to rule out or support the diagnosis
of ODRI. Clinicians typically weigh multiple clinical signs and
symptoms, laboratory findings, and radiographic results in a
nonstandardized fashion before diagnosing a case of ODRI.
The likelihood ratio (LR) determines the performance of a
test in a standardized fashion. It expresses the ratio of the
chance that a given diagnostic test result would be observed
for a patient with the target disease relative to the chance that
it would be observed for a patient without the disease [49].
The LR positive is calculated as follows: sensitivity/(1  spec-
ificity). The LR negative is determined as follows: (1  sensi-
tivity)/specificity. Pretest odds are estimated by the following
equation: pretest probability/(1  pretest probability). Posttest
odds are computed by multiplying the pretest odds by the LR
positive or negative, respectively. The posttest odds convert
back into posttest probability by the following relationship:
probability p odds/(1  odds). Tests with an LR positive of
10 or an LR negative of 0.1 are considered excellent. Table
4 summarizes estimated LRs for various tests based on pub-
lished studies cited in MEDLINE between 1975 and 2000. Cal-
culation is facilitated by using a nomogram available from mul-
tiple sources (e.g., http://cebm.jr2.ox.ac.uk/docs/nomogram
.html). For example, a clinician evaluates a patient with sus-
pected ODRI. Presence of a normal ESR and CRP level basically
rules out the presence of ODRI. Clinical evaluation may provide
evidence that a patient has ODRI, with a pretest probability of
up to 50%, translating to odds of 1:1. The posttest odds for a
normal ESR is calculated by multiplying the pretest odds (1)
times the LR negative (0.18), resulting in 0.18. The posttest
probability, 0.18/(1 0.18), is converted into a 15% probability
that the patient has the disease. The same calculation is repeated
with the normal CRP value, which provides a negative LR of
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Table 5. Treatment options for patients with orthopedic
device–related infection.
Option
Debridement with retention of prosthesis and long-term
treatment with antimicrobial agents
Girdlestone arthroplasty
One-stage replacement with or without use of antimicrobial
cement and long-term treatment with antimicrobial agents
Two-stage replacement with or without use of antimicrobial
cement and long-term treatment with antimicrobial agents
Suppressive antimicrobial therapy
Arthrodesis
Amputation
0.05. The posttest probability that the patient has the disease
is now !1%.
Such calculations quantify the clinical experience that pres-
ence of a normal ESR and CRP level basically rules out the
presence of ODRI [50]. CRP levels are always elevated after
surgery but should return to normal within 2–3 weeks [79].
Therefore, an elevated CRP level must be interpreted in the
context of its natural course. Another example is the value of
the intraoperative Gram’s stain: A positive result (LR positive,
8.5) strongly supports the diagnosis of ODRI whereas a negative
result (LR negative, 0.94) basically does not influence the pretest
probability. Many authors in fact recommend abandoning this
latter test [72]. In my opinion, a posttest probability of 95%
is sufficient for diagnosing and treating ODRIs. However, spe-
cialized infectious diseases physicians and orthopedic surgeons
with long-term experience are frequently necessary for optimal
management of patients with ODRI.
A common workup for ODRI includes testing of WBCs and
polymorphonuclear leukocytes, including a left shift, ESR and
CRP determinations, plain radiographs, and aspiration arthro-
grams with several specimens for culture. Scintigraphy by
means of a technetium (Tc99m) scan, gallium citrate (Ga67) scan,
or indium (In111)-labeled leukocyte scan may be helpful in the
diagnosis of ODRI. However, this approach is expensive, and
the accuracy of these methods is still limited. They frequently
fail, especially in equivocal situations in which standard radio-
graphs are unable to distinguish between septic and aseptic
loosening of the implant [38]. Intraoperative cultures should
always be combined with histopathology (see below).
Standardized criteria for establishing the diagnosis of ODRI
are lacking, and even though most studies use similar sets of
criteria, they are not identical. The following are the criteria
most studies use: (1) purulence surrounding the prosthesis at
the time of debridement and isolation of the same pathogens
in 2 specimens and a positive frozen section from a biopsy
[42]; (2) systemic signs and symptoms of infection and pain
at the site of the device without another obvious source, pu-
rulent fluid in the joint or around a fixation device, and iso-
lation of at least 1 pathogen from aspiration or intraoperative
culture—the criteria for early, postoperative acute infection [11,
15]; (3) clinical signs and symptoms of ODRIs with a positive
culture result and positive results of histopathology; or (4) the
presence of a sinus tract communicating with the prosthesis or
internal fixation device, indicating chronic infection [50]. Some
researchers use only microbiological criteria and define im-
plant-associated infection by isolating a single pathogen from
3 different specimens [80]. Many other criteria are used but
have not been validated and were applied on retrospective data.
MICROBIOLOGICAL CULTURES
The reference standard for diagnosing infection is the isolation
of the responsible pathogen. However, standard microbiological
cultures are only moderately sensitive and specific for diag-
nosing ODRIs. A very low inoculum, adherent bacteria, and
the formation of small-colony variants of S. aureus may limit
detection. In addition, concurrent treatment with antimicrobial
agents before sampling can prevent growth in the laboratory.
Technical issues that can affect culture results include poor
positioning of the aspiration needle or the addition of local
anesthetic to the inflamed joint fluid.
Preoperative aspiration is probably the most useful tool to
rule out the presence of ODRI or to confirm a clinically sus-
pected ODRI [10]. The position of the needle should preferably
be documented by arthrography or ultrasonography. The
pathogen may be isolated from a synovial biopsy in cases of a
dry tap. Three specimens should be sent to the laboratory for
accurate interpretation of the results. The diagnosis of ODRI
is established when all 3 specimens demonstrate growth of the
same microorganism [80] and the patient has clinically sus-
pected ODRI. Superficial sinus tract cultures are misleading,
and only isolation of S. aureus may indicate the true infecting
pathogen in osteomyelitis [81].
Intraoperative cultures provide the most accurate specimens
for microbiological cultures and are frequently used as the ref-
erence standard for diagnosing ODRI. Simple technical prob-
lems, such as routine antimicrobial prophylaxis before sam-
pling, delay in sending the specimens to the laboratory, failure
to ask for anaerobe cultures, and sending in swabs instead of
biopsy material, may limit the ability of the laboratory to isolate
the microorganism. A minimum of 3 specimens should be sent
to the laboratory [80]. The implant, if available, should be
cultured as well [11, 45, 82]. Sonication may increase the sen-
sitivity of the culture technique by dispersing adherent bacteria
[82].
Molecular techniques are powerful tools that significantly
enhance the detection of a microorganism. 16S rRNA gene
amplification allows detection of any bacteria that do not grow
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Table 6. Results of studies evaluating treatment of orthopedic device–related infections with device retention.
Pathogen Treatment (dosage) Duration
Unstable
devices
included
Cure as
treated
(%) Reference
Staphylococcus aureus, coagulase-
negative staphylococci
Ciprofloxacin (750 mg b.i.d.), rifampin (450 mg b.i.d.) 3 moa No 100 [11]
Ciprofloxacin (750 mg b.i.d.), rifampin (450 mg b.i.d.) 30 mo No 100 [15]
Fusidic acid (500 mg b.i.d./t.i.d.), rifampin (450 mg b.i.d.) 6 mo Yes 57 [14]
Ofloxacin (200 mg t.i.d.), rifampin (450 mg b.i.d.) 6 mo Yes 57 [14]
Various NS Yes 31 [12]
Various 14 wk No 71 [40]
Methicillin-resistant S. aureus TMP-SMX (20/100 mg/kg) 16 mo Yes 43 [90]
Pseudomonas aeruginosa Ceftazidime (1000 mg t.i.d.), ciprofloxacin (500 mg t.i.d.) 6 mob Yes 93 [91]
NOTE. In most studies, antimicrobial therapy was begun iv. mo, month; NS, not standardized; TMP-SMX, trimethoprim-sulfamethoxazole; wk, week.
a Results from patients who completed trial are reported; cure rates from intent-to-treat analysis are slightly lower.
b Ceftazidime for 6 weeks.
in routine culture or bacteria in a very low inoculum [45]. 16S
rRNA–directed in situ hybridization may be less susceptible to
cross-contamination [83]. These newer molecular techniques,
however, do not provide susceptibility testing, a prerequisite
for accurate treatment of ODRIs. In addition, they are not
widely available, and identification of species requires bacterial
sequencing or specific primers. As of today, more research is
necessary to introduce such techniques in a routine microbi-
ology laboratory for the identification of microorganisms in
ODRIs.
HISTOPATHOLOGY
Any single high-power field that contains at least 5 stromal neu-
trophil granulocytes strongly suggests infection [84]. Frozen in-
traoperative sections correlate well with the permanent section
of the capsular or granulation tissue [55]. Permanent sections
improve sensitivity by ∼10% compared with frozen sections, but
the specificity is 195% with both methods [85]. Frozen sections
facilitate or allow the diagnosis of ODRI and help to distinguish
true infection from contamination (table 4). The accuracy of
this technique depends on the experience and training of the
histopathologist and the proper sampling of specimens from
clinically inflamed tissue. Interobserver variability appears to
be substantial, even in specialized institutions [10]. Moreover,
sampling errors will lead to false-negative results. Interpretation
of frozen sections from patients with rheumatoid arthritis and
other nonbacterial joint infections is difficult. However, frozen
sections are part of the most powerful tests in diagnosing ODRI
(median LR positive, 20). The combination of 2 independent
tests—histopathologic and microbiological—allows an accurate
diagnosis and should be used as the current reference standard
for diagnosing ODRI. The cutoff for a positive result is still a
matter of debate. Lonner et al. [85] proposed the use of 10
instead of 5 polymorphonuclear leukocytes per high-power
field (400) to increase the specificity of the result to 99%.
Unfortunately, the number of areas to be scanned in frozen
sections is not standardized.
TREATMENT
Several options for treatment of ODRIs have been established
(table 5) and depend on multiple factors such as type of in-
fection (acute vs. chronic), the isolated pathogen and its sus-
ceptibility pattern, the fixation of the device, the quality and
availability of the bone stock, and the training and experience
of the orthopedic surgeon and the infectious diseases physician.
Most authors recommend the removal of the device to eradicate
chronic infection [2, 13, 86, 87]. Patients with chronic infec-
tions are not likely to respond to antimicrobial therapy alone
and always require removal of the implant [2, 88]. A loose
prosthesis cannot be successfully treated without removal of
the implant [89]. However, many studies provide ample evi-
dence that a subset of patients with acute ODRI can be suc-
cessfully treated with retention of the device (tables 6 and 7).
Criteria for optimal selection of patients for this type of treat-
ment are summarized in table 2.
Early postoperative infection. Treatment of these early
postoperative infections must be guided by an orthopedic sur-
geon and an infectious diseases physician trained in manage-
ment of ODRIs [43]. Patients presenting with fever, redness,
pain, and drainage early after surgery should never be treated
with antimicrobial agents before a thorough diagnostic workup
has been done. The preferred method, especially for patients
with hematoma, is extensive and meticulous debridement that
allows the taking of multiple biopsy samples from clinically
infected tissue around the implant and multiple microbiological
samples, including anaerobic cultures. Prophylactic antibiotics
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should be withheld until the joint capsule has been incised and
accurate specimens for histopathology and culture have been
obtained [89]. This debridement must be done immediately
after the onset of signs and symptoms of infection to prevent
potential biofilm formation of the infecting pathogen and sub-
sequent resistance to antimicrobial therapy [13, 21]. Preoper-
ative aspiration may be an alternative, but cultures can be falsely
negative.
Patients eligible for treatment with antimicrobial agents and
salvage of the prosthesis or implant should meet all criteria
listed in table 2. Initial treatment with antimicrobial agents
should always be given iv. There is a current debate on how
long treatment should be continued iv. The minimum duration
supported by most authors is 2 weeks [11]. Tsukayama et al.
[40] have recommended 4 weeks and other authors [2] 6 weeks.
The treatment can be changed to oral therapy for a minimum
of 3 months for internal fixation devices and hip prostheses
and for 6 months for total knee prostheses [11, 15, 91, 93].
The isolated pathogen and its susceptibility pattern will guide
the choice of antimicrobial therapy, on the basis of results of
clinical studies (table 7). As mentioned above, the susceptibility
pattern is useful only to exclude antimicrobial agents without
in vitro efficacy. However, MICs demonstrate a poor correlation
with clinical outcome. Serum bactericidal titers or MBCs with
stationary-phase bacteria correlate much better with clinical
outcome but are rarely available in the clinical setting [11, 15,
30]. The dosage of the treatment with antimicrobial agents
should be as high as clinically possible. Ciprofloxacin failed to
cure any tissue cages infected with S. epidermidis in the foreign
body animal model, although trough levels of the antibiotic
exceeded the MIC [30]. This failure correlated well with the
poor in vitro efficacy against stationary-phase S. epidermidis.
In contrast, ciprofloxacin was highly effective against station-
ary-phase S. dublin, and a case of ORDI with Salmonella was
successfully treated with ciprofloxacin [17].
The BEC is usually 10–100 times higher than the regular
MIC [34]. Rifampin has excellent efficacy against stationary-
phase staphylococci, exceeds MICs at trough levels by a factor
of 10–100, and is orally well absorbed. In addition, this drug
has been shown to eliminate stationary-phase staphylococci in
vitro, in an animal model with foreign body infections, and in
clinical trials of ODRIs [11, 14, 15, 30]. Therefore, rifampin
should always be included in the treatment of staphylococcal
ODRIs if the strain is susceptible in vitro.
However, selection of resistant mutants occurs within days
of rifampin monotherapy. Therefore, rifampin must be com-
bined with another antimicrobial agent, preferably a quinolone.
Quinolones effectively prevent the emergence of rifampin re-
sistance if given concurrently. However, once resistance occurs,
treatment should not be continued, even if the strain remains
susceptible to quinolones. Data on treatment have been gen-
erated with such first-generation quinolones as ciprofloxacin
or ofloxacin. The newer quinolones, such as moxifloxacin or
gemifloxacin, have much lower MICs for staphylococci than
the older quinolones and might be preferred as partner to
rifampin. However, no clinical data are available.
The outcome of antimicrobial therapy appears to be asso-
ciated with pharmacodynamic parameters. The optimal para-
meter of outcome for b-lactam antibiotics is probably the time
above MIC [94]. Therefore, one should aim to exceed the MIC
at trough levels for treatment with b-lactam antibiotics. The
area under the inhibition curve (AUIC) might be the best pre-
dictor for quinolone therapy [95]. The precise MIC should be
determined for susceptible pathogens known to be close to the
break point. Evidence for this hypothesis has been generated
for P. aeruginosa and ciprofloxacin. Studies [96, 97] indicate a
correlation between the AUIC and the emergence of quinolone
resistance. Therefore, combination therapy with a b-lactam
antibiotic and tobramycin is recommended during iv therapy
before switching to oral ciprofloxacin [91].
The patient should be closely monitored during treatment.
Parameters to be recorded are clinical signs and symptoms of
infection, WBC count, CRP level, ESR, and, less frequently,
radiographic results. However, these parameters did not predict
failure of treatment during the early course of therapy in a
prospective study [11]. They are useful to identify failure of
therapy, but a normal range of these parameters does not pre-
clude relapse after withdrawal of antimicrobial therapy. Treat-
ment should be continued for a minimum of 3 months for
total hip prostheses and internal fixation devices or for 6
months for total knee prostheses. It should be continued for
a maximum of 1 year if clinical or laboratory parameters have
not normalized. Follow-up after completing antimicrobial ther-
apy is crucial to identify failure of the treatment as early as
possible.
Of importance, these recommendations apply only in the
case of early postoperative infections that respond by 180% to
this regimen. In my experience, longer intervals from surgery
to the onset of infection (1–3 months) might be acceptable for
pathogens with low virulence, such as CNS or Propionibacter-
ium species [13]. However, failure rates are likely to be higher
compared with immediate removal of the implant and treat-
ment with antimicrobial agents.
Chronic infection. The diagnosis of chronic infection may
be very difficult, because signs and symptoms may be absent.
Aspiration with or without arthrography can help to distinguish
infection from aseptic loosening of the implant. The presence
of a sinus tract communicating with the prosthesis or internal
fixation device implies definite chronic infection [50]. Treat-
ment always calls for removal of the implant and a 1-stage or
2-stage revision arthroplasty.
Infections due to CNS are frequently treated with a 1-stage
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approach, if the quality of the bone stock is appropriate [98,
99]. Antibiotic-containing cement is commonly used but may
be associated with subsequent aseptic loosening. Ure et al. [99]
reviewed the failure rate after a 1-stage and a 2-stage approach
and found no significant difference. However, infections due
to low-virulence microorganisms are likely to be treated with
a 1-stage approach, introducing a serious selection bias. Most
orthopedic surgeons favor a 2-stage approach for frankly pu-
rulent infections due to a virulent pathogen, such as methicillin-
resistant S. aureus. Such cases are treated by removing the im-
plant, vigorous debridement, and 2–6 weeks of iv antimicrobial
therapy before reinsertion of a new implant. Antimicrobial
therapy may be discontinued before implantation of the new
device to allow optimal conditions for intraoperative cultures.
After the histopathologic specimens have been taken, antimi-
crobial prophylaxis should be infused before inserting the new
implant.
Cultures may reveal additional pathogens or persistence of
the isolated pathogens. Both results will influence treatment
with antimicrobial agents and postoperative management. Neg-
ative culture results document successful treatment, allowing
treatment with antimicrobial agents to be shortened after reim-
plantation. Antimicrobial prophylaxis should be given after bi-
opsies and cultures to reduce the risk of reinfection of the new
prosthesis. Such management may increase the risk for super-
ficial surgical site infection but allow tailored treatment with
antimicrobial agents. Surgical choice between a 1-stage or 2-
stage approach and type and duration of antimicrobial therapy
are poorly standardized and depend on the personal experience
and local experts [38]. Other types of management, such as
suppressive antimicrobial therapy, for patients not fit for sur-
gery are beyond the scope of this review [100]. Excellent reviews
of additional therapeutic options have been published elsewhere
[2, 38, 89, 101].
In conclusion, treatment of ODRIs relies on an accurate
classification, unambiguous diagnosis, and isolation of the in-
fecting pathogen with its susceptibility pattern. Recent reports
suggest that early postoperative infections can be successfully
treated with debridement and long-term antimicrobial therapy.
Patients must meet criteria such as a stable implant and good
quality of bone stock; rapid treatment after onset of infection
and orally available antimicrobial agents effective against the
isolated pathogen are absolute requirements. In addition, the
patient must be compliant and tolerate long-term antimicrobial
therapy. This new option for a subset of patients will help to
prevent the morbidity and mortality that were associated with
the surgical 2-stage approach of treating ODRIs.
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